Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - BR36
BR36 Details
Status: Closed 
Activation Date: 2019OCT17
Closing Date: 2022APR05
Phase: II 

Description: A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer 

Eligibility: Eligibility: MAIN INCLUSION CRITERIA: Patients with metastatic NSCLC that is EGFR and ALK mutation negative, PD-L1 expression Tumour Proportion Score (TPS) ? 50% who are willing and able to receive continued pembrolizumab or addition of standard platinum-based combination therapy added to pembrolizumab after initial 6 weeks (after 2 Q3W doses or 1 Q6W dose) of pembrolizumab as systemic immunotherapy. ECOG 0-2. Clinically/radiologically evaluable disease, RECIST 1.1 measurable disease not required. Mandatory blood collection of ctDNA for screening. MAIN EXCLUSION CRITERIA: Symptomatic/unstable CNS metastases. Patients who are not suitable candidates for treatment with pembrolizumab as a single agent or in combination with standard platinum combination chemotherapy. 

Objective: Primary: Phase II progression free survival (PFS), Phase III overall survival (OS). Secondary: Phase II feasibility, RECIST response rate post randomization, safety/tolerability; Phase III RECIST response rate post randomization, response duration, progression free survival, and safety/tolerability. 

Participation: Open to member centres 

Lay Description: This is planned as a two stage study. Stage 1 of the study will evaluate if blood tests can be used to see how the cancer responds to treatment with pembrolizumab. Stage 2 will be finalized once stage 1 is completed with a plan to use blood tests to evaluate if patients whose cancer does not seem to be getting better on treatment with pembrolizumab would do better on a different treatment.  

Primary Publication Show

Other Publications Show

Inventory
Hide Tissue Samples
Disease Site Trial Code Patients Accrued Patients - Blocks Patients - Slides Patients - Blocks and/or Slides
LUNG BR36 50 19 0 19
Hide TMA Samples
(Core size is 0.6 mm)
Disease Site Trial Code Patients Accrued TMA Blocks Patients on TMA Blocks
LUNG BR36 50 0 0
Hide Fluid Samples
Disease Site Trial Code Patients Accrued Patients - Whole Blood Patients - Cellular Component of Blood Patients - DNA extracted from Blood Patients - RNA extracted from Blood Patients - Plasma Patients - Serum Patients - Urine Patients - Buccal
LUNG BR36 50 0 0 0 0 50 0 0 0